開示日時：2022/03/23 16:00:00
損益
| 決算期 | 売上高 | 営業益 | 経常益 | EPS |
| 2018.01 | 49,051 | -437,838 | -369,838 | -86.85 |
| 2019.01 | 74,161 | -373,392 | -278,305 | -60.17 |
| 2020.01 | 44,723 | -548,607 | -499,297 | -100.91 |
| 2021.01 | 0 | -580,174 | -580,150 | -65.38 |
※金額の単位は［万円］
株価
| 前日終値 | 50日平均 | 200日平均 | 実績PER | 予想PER |
| 1,250.0 | 1,119.82 | 1,289.22 | – | -31.95 |
※金額の単位は［円］
キャッシュフロー
| 決算期 | フリーCF | 営業CF |
| 2018.01 | -193,927 | -190,677 |
| 2019.01 | -397,470 | -396,834 |
| 2020.01 | -582,424 | -571,729 |
| 2021.01 | -535,444 | -521,568 |
※金額の単位は［万円］
▼テキスト箇所の抽出
March 11, 2022 Company name: SanBio Co., Ltd. Representative: Keita Mori, Representative Director Contact: Yoshihiro Kakutani, Corporate Officer and President (TSE Mothers Code: 4592) of Management Administration (TEL. +81-3-6264-3481) Recording of Non-Operating Expenses (Financing Expenses) SanBio Company Limited (the “Company”) hereby announces the recording of non-operating expenses (financing expenses) in the fiscal year ended January 31, 2022 (February 1, 2021–January 31, 2022). 1. Overview of non-operating expenses (financing expenses) The Company recorded financing expenses of 10 million yen as non-operating expenses in the fiscal year ended January 31, 2022. These expenses mainly came from fees related to the committed credit line agreement the Company entered into with three banks. Impact on earnings performance Regarding the impact of the non-operating expenses (financing expenses) on the Company’s earnings performance, please see the “Consolidated Financial Results for the Fiscal Year Ended January 31, 2022 (Japanese GAAP)” released March 11, 2022. 2.
